Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAYBREAK: Lanabecestat in Mild Alzheimer's Disease Dementia
jRCT2080223444Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Jan 2017; status: terminated.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223444.